Bundibugyo ebolavirus, or BDBV
Why in News?
The World Health Organization (WHO) declared the ongoing Bundibugyo ebolavirus (BDBV) outbreak in the Democratic Republic of the Congo (DRC) and Uganda a Public Health Emergency of International Concern (PHEIC).
Core Facts & Transmission
- Pathogen Identity: BDBV is a zoonotic virus belonging to the Orthoebolavirus genus, making it one of the distinct species that cause Ebola Virus Disease (EVD) in humans.
- Discovery History: The virus was first identified in 2007 during an outbreak in the Bundibugyo District of western Uganda.
- Natural Reservoir: Fruit bats are considered the most likely natural reservoir for the pathogen.
- Spillover & Spread: Humans contract the virus via direct contact with infected wildlife (like bats and primates). It then spreads person-to-person through direct contact with blood, secretions, organs, or other bodily fluids.
- Contagion Timeline: The incubation period lasts between 2 to 21 days. Individuals do not become contagious until they actively display symptoms.
- Clinical Symptoms: Patients experience severe, rapid-onset symptoms including high fever, generalized body pain, extreme weakness, vomiting, and internal or external bleeding.
The Recent Outbreak Status
- Epicentre & Spread: The primary epicentre is the Ituri Province in northeastern DRC, but infections have actively crossed borders into Uganda (including cases detected in Kampala).
- Current Toll: There are hundreds of confirmed and suspected cases across multiple health zones, resulting in dozens of deaths.
- Fatality Profile: Historically and during active monitoring, the case fatality rate for the Bundibugyo strain ranges between 25% to 50%.
- Compounding Challenges: Managing the crisis is highly complicated due to severe regional insecurity, high population mobility around mining sites, community mistrust, and cross-border transit.
Critical Medical and R&D Gaps
- Vaccine Mismatch: Highly effective, licensed Ebola vaccines (like those used in past epidemics) specifically target the Zaire ebolavirus species and do not provide proven protection against the Bundibugyo species.
- Diagnostic Delay: The outbreak went undetected for weeks because standard, rapid diagnostic tests widely available in Africa only detect the Zaire strain. Confirming BDBV requires specialized molecular laboratory testing.
- Experimental Drugs: The WHO is urgently reviewing experimental medical options. Laboratory and animal data indicate potential alternative treatments, including Regeneron's antibody drug maftivimab, Gilead Sciences' oral antiviral obeldesivir, and the antiviral remdesivir.
Download Pdf
